Recent commentary on Cardinal Health (CAH) has focused on expectations for stronger quarterly earnings and revenue across core segments, along with value oriented ratings and fresh share price highs relative to sector peers.
See our latest analysis for Cardinal Health.
At a share price of US$236.40, Cardinal Health has given investors a 28.72% 90 day share price return and a 51.74% 1 year total shareholder return. This signals strong momentum despite a slight pullback in the latest session, as leadership changes and product recall headlines share the stage with upbeat earnings expectations.
If you are assessing how this kind of momentum compares across healthcare, it can help to widen your watchlist with a curated Simply Wall St screener of 43 healthcare AI stocks.
After a move like Cardinal Health’s, some investors think about locking in recent gains, while others wonder if it is only the start. The next step is to see what the current valuation really suggests about buying now versus waiting.
Most Popular Narrative: 5.6% Undervalued
Cardinal Health’s most followed narrative tags a fair value of about $250.53 against the last close at $236.40, which frames the current move as slightly below that valuation anchor and puts the focus firmly on execution and earnings quality.
The analysts have a consensus price target of $250.53 for Cardinal Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $215.0.
Want to understand why this fair value sits above today’s price yet still assumes only moderate earnings and margin expansion? The narrative focuses on steady revenue compounding, cautious profit improvement and a future earnings multiple that edges above sector averages. It also considers which specific growth and profitability paths would need to align to keep that valuation intact.
Result: Fair Value of $250.53 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to watch for tighter government pricing and reimbursement pressure, along with major customer contract changes, which could quickly challenge the current Cardinal Health narrative.
Find out about the key risks to this Cardinal Health narrative.
Another View on Cardinal Health’s Valuation
The earlier analyst narrative frames Cardinal Health as about 5.6% undervalued against its US$250.53 fair value. The market’s own P/E tells a different story. At 35.6x earnings, the stock trades above US Healthcare at 25.3x and above its fair ratio of 31.8x, which points to richer pricing and less room for disappointment if earnings slip.
This kind of gap can still work for investors who think current growth and execution will hold up. However, it raises the question of how much margin of safety you really have if sentiment cools and the market leans back toward that fair ratio benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If you are unsure how to balance caution about risks with optimism about potential rewards, take a closer look at the underlying data and form your own view, then check the 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Cardinal Health?
If Cardinal Health has you thinking harder about valuation and momentum, do not stop here. Broaden your watchlist with a few carefully filtered stock ideas.
- Target dependable cash flows and pricing power by reviewing companies highlighted in the 51 high quality undervalued stocks.
- Prioritise resilience and capital preservation by checking stocks filtered through the 79 resilient stocks with low risk scores.
- Spot potential early stage opportunities with solid financial footing via the 20 elite penny stocks with strong financials.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com